We are live on ! Find out more
RNTX

Rein Therapeutics
RNTX

27 hedge funds and large institutions have $8.49M invested in Rein Therapeutics in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 8

0.53% less ownership

Funds ownership: 7.62% → 7.09% (-0.53%)

18% less funds holding

Funds holding: 33 → 27 (-6)

28% less capital invested

Capital invested by funds: $11.8M → $8.49M (-$3.34M)

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
27
Holders Change
-6
Holders Change %
-18.18%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
12
Reduced
8
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$403K
2
Millennium Management
Millennium Management
New York
+$166K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$114K
4
Morgan Stanley
Morgan Stanley
New York
+$85.2K
5
State Street
State Street
Massachusetts
+$48.1K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$1.32M
2
Squarepoint
Squarepoint
New York
-$117K
3
ECM
Endurant Capital Management
California
-$91.8K
4
Norges Bank
Norges Bank
Norway
-$68.3K
5
TCIM
TIAA CREF Investment Management
New York
-$68K

RNTX Hedge Fund Activity: Q1 2018 in Review

27 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q1 2018, worth a combined $8.49M — down 28% from $11.8M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of RNTX and 1 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 12 added.

The largest buyer was Jennison Associates, adding an estimated $403K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $1.32M sold.

  • 27 institutional investors held Rein Therapeutics (RNTX) as of Q1 2018, down from 33 in Q4 2017.
  • Funds reported $8.49M of Rein Therapeutics stock for Q1 2018, down 28% quarter-over-quarter.
  • 1 fund opened new Rein Therapeutics positions in Q1 2018 and 7 closed out, a net change of -6 holders.
  • The largest Rein Therapeutics buyer in Q1 2018 was Jennison Associates, an estimated $403K added.
  • The largest Rein Therapeutics seller in Q1 2018 was Sphera Funds Management, an estimated $1.32M sold.

Based on aggregated 13F filings for Q1 2018.